BioCentury | Dec 7, 2015
Clinical News

TPI 287: Additional Phase I/II data

...in the open-label, dose-escalation, U.S. Phase I/II Study CB-017 showed that 140-220 mg/m 2 IV TPI 287...
...of the trial, patients will receive Avastin alone or in combination with the MTD of TPI 287...
...from the trial (see BioCentury, May 18). Cortice Biosciences Inc. , New York, N.Y. Product: TPI 287...
BioCentury | Dec 7, 2015
Clinical News

TPI 287: Interim Phase I/II data

...in the open-label, dose-escalation, U.S. Phase I/II Study CB-018 showed that 140-180 mg/m 2 IV TPI 287...
...Society for Neuro-Oncology meeting in San Antonio. Cortice Biosciences Inc. , New York, N.Y. Product: TPI 287...
BioCentury | May 18, 2015
Clinical News

TPI 287: Interim Phase I/II data

...in the open-label, dose-escalation, U.S. Phase I/II CB-017 trial showed that 140-180 mg/m 2 IV TPI 287...
...of the trial, patients will receive Avastin alone or in combination with the MTD of TPI 287...
...Association for Cancer Research meeting in Philadelphia. Cortice Biosciences Inc. , New York, N.Y. Product: TPI 287...
BioCentury | Mar 2, 2015
Emerging Company Profile

The road to Tau

...PSP. At least one company has a more advanced PSP program. Cortice Biosciences Inc .'s TPI 287...
BioCentury | Jan 26, 2015
Clinical News

TPI 287: Phase I started

...Center and Research Institute began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV TPI 287...
...cancer or non-small cell lung cancer (NSCLC). Cortice Biosciences Inc. , New York, N.Y. Product: TPI 287...
BioCentury | Nov 17, 2014
Clinical News

TPI 287: Interim Phase I/II data

...in the open-label, dose-escalation, U.S. Phase I/II CB-017 trial showed that 140-170 mg/m 2 IV TPI 287...
...There were 2 cases of grade 3 myelosuppression which were regarded as possibly related to TPI 287...
...for TPI 287 plus Avastin is established, patients will receive Avastin alone or in combination with TPI 287...
BioCentury | Jul 21, 2014
Clinical News

TPI 287: Phase I started

...placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate 2, 6.3 and 20 mg/m 2 IV TPI 287...
...TPI 287 for an additional 6 weeks. The non-profit CBD Solutions is partially funding the trial. TPI 287...
...designation in the U.S. to treat PSP. Cortice Biosciences Inc. , New York, N.Y. Product: TPI 287...
BioCentury | Mar 31, 2014
Clinical News

TPI 287: Phase II started

...Cortice began a 2-stage, open-label, dose-escalation, U.S. Phase II trial of IV TPI 287 every 3 weeks...
...the MTD for TPI 287 is established, patients will receive Avastin alone or in combination with TPI 287...
...the U.S., while Roche markets it elsewhere. Cortice Biosciences Inc. , New York, N.Y. Product: TPI 287...
BioCentury | Feb 10, 2014
Clinical News

TPI 287: Phase I started

...placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate 2, 6.3 and 20 mg/m 2 IV TPI 287...
...receive TPI 287 for an additional 6 weeks. Cortice Biosciences Inc. , New York, N.Y. Product: TPI 287...
BioCentury | Jan 20, 2014
Clinical News

TPI 287: Phase II started

...Cortice began a 2-stage, open-label, dose-escalation, U.S. Phase II trial of IV TPI 287 every 3 weeks...
...the MTD for TPI 287 is established, patients will receive Avastin alone or in combination with TPI 287...
...the U.S., while Roche markets it elsewhere. Cortice Biosciences Inc. , New York, N.Y. Product: TPI 287...
Items per page:
1 - 10 of 36